Further studies on imidazo[4,5-b] pyridine AT1 angiotensin II receptor antagonists.: Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds

被引:80
作者
Cappelli, Andrea
Mohr, Gal. la Pericot
Giuliani, Germano
Galeazzi, Simone
Anzini, Maurizio
Mennuni, Laura
Ferrari, Flora
Makovec, Francesco
Kleinrath, Eva M.
Langer, Thierry
Valoti, Massimo
Giorgi, Gianluca
Vomero, Salvatore
机构
[1] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[2] Univ Siena, European Res Ctr Drug Discovery & Dev, I-53100 Siena, Italy
[3] Rotta Res Lab SpA, I-20052 Monza, Italy
[4] Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria
[5] Univ Siena, Dipartimento Sci Biomed, I-53100 Siena, Italy
[6] Univ Siena, Dipartimento Chim, I-53100 Siena, Italy
关键词
D O I
10.1021/jm0603163
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 4-phenylquinoline fragment of novel AT(1) receptor antagonists 4 based on imidazo[ 4,5-b] pyridine moiety was replaced by 4-phenylisoquinolinone (compounds 5) or 1-phenylindene (compounds 6) scaffolds to investigate the structure-activity relationships. Binding studies showed that most of the synthesized compounds display high affinity for the AT(1) receptor. Because of the in vitro high potency of carboxylic acids 5b, f, they were evaluated in permeability (in Caco-2 cells) and in pharmacokinetic studies in comparison with quinoline derivatives 4b, i, j, k. The studies showed that these compounds are characterized by rapid excretion, low membrane permeability, and low oral bioavailability. The structure optimization of the indene derivatives led to compounds 6e, f possessing interesting AT(1) receptor affinities. Optimization produced polymerizing AT(1) receptor ligand 6c, which forms a thermoreversible polymer (poly-6c) and is released from the latter by a temperature-dependent kinetics. The results suggest the possibility of developing novel polymeric prodrugs based on a new release mechanism. Finally, a set of 34 AT(1) receptor antagonists was used as a new test for the evaluation of the predictive capability of the previously published qualitative and quantitative pharmacophore models.
引用
收藏
页码:6451 / 6464
页数:14
相关论文
共 38 条
[1]  
*ACC INC, 2002, CAT VERS 4 7 SOFTW P
[2]   Diphenylpropionic acids as new AT(1) selective angiotensin II antagonists [J].
Almansa, C ;
Gomez, LA ;
Cavalcanti, FL ;
deArriba, AF ;
Rodriguez, R ;
Carceller, E ;
GarciaRafanell, J ;
Forn, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (11) :2197-2206
[3]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[4]   The new angiotensin II receptor antagonist, irbesartan - Pharmacokinetic and pharmacodynamic considerations [J].
Brunner, HR .
AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) :311S-317S
[5]   New π-stacked benzofulvene polymer showing thermoreversible polymerization:: Studies in macromolecular and aggregate structures and polymerization mechanism [J].
Cappelli, A ;
Anzini, M ;
Vomero, S ;
Donati, A ;
Zetta, L ;
Mendichi, R ;
Casolaro, M ;
Lupetti, P ;
Salvatici, P ;
Giorgi, G .
JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY, 2005, 43 (15) :3289-3304
[6]   Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT1 angiotensin II receptor antagonists based on the 4-phenylquinoline structure [J].
Cappelli, A ;
Mohr, GL ;
Gallelli, A ;
Rizzo, M ;
Anzini, M ;
Vomero, S ;
Mennuni, L ;
Ferrari, F ;
Makovec, F ;
Menziani, MC ;
De Benedetti, PG ;
Giorgi, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2574-2586
[7]   Synthesis and characterization of a new benzofulvene polymer showing a thermoreversible polymerization behavior [J].
Cappelli, A ;
Mohr, GL ;
Anzini, M ;
Vomero, S ;
Donati, A ;
Casolaro, M ;
Mendichi, R ;
Giorgi, G ;
Makovec, F .
JOURNAL OF ORGANIC CHEMISTRY, 2003, 68 (24) :9473-9476
[8]   NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - THE DISCOVERY OF A SERIES OF N-(BIPHENYLYLMETHYL)IMIDAZOLES AS POTENT, ORALLY ACTIVE ANTIHYPERTENSIVES [J].
CARINI, DJ ;
DUNCIA, JV ;
ALDRICH, PE ;
CHIU, AT ;
JOHNSON, AL ;
PIERCE, ME ;
PRICE, WA ;
SANTELLA, JB ;
WELLS, GJ ;
WEXLER, RR ;
WONG, PC ;
YOO, SE ;
TIMMERMANS, PBMWM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) :2525-2547
[9]  
CHAKRAVARTY PK, 1994, Patent No. 5332744
[10]  
CHANG RSL, 1992, J PHARMACOL EXP THER, V262, P133